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Abstract The expression and function of p53 tumor suppressor 
protein was investigated in T-cells immortalized by the Taxi 
protein of HTLV-I. Conformationally wild-type p53 was 
expressed at elevated levels in Taxi-immortalized T-cells by 
post-transcriptional mechanisms when compared with normal T-
cells. Luciferase assays with a reporter plasmid containing p53-
binding sites revealed an impairment in the transactivating 
function of p53 in Taxi-immortalized T-cells. Our results 
suggest an important role for Taxi in the aberrant expression 
and function of p53 observed in many HTLV-I transformed cells. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
H u m a n T-cell leukemia virus type I (HTLV-I) is the etio-
logical agent of adult T-cell leukemia (ATL), and this virus 
can transform normal T-cells in vitro [1,2]. T a x i , a transcrip-
tional /rans-activator of this virus, is thought to be responsible 
for this process [1,3,4]. Primary human T-cells can be immor-
talized by T a x i , and these Taxi-immortal ized T-cells exhibit 
many features similar to those of HTLV-I-transformed T-cells 
[5-7]. Transcriptional activation of cellular genes by T a x i is 
thought to lead to T-cell transformation, but the precise 
mechanism of this process is still unclear. 
Recently, it has been reported that the majority of HTLV-I-
transformed T-cells show elevated steady-state levels of tumor 
suppressor p53 protein compared to normal human peripheral 
blood lymphocytes [8-10]. Although increased p53 protein 
levels are usually associated with missense mutat ions in the 
evolutionarily conserved domain of the p53 gene, most 
HTLV-I-transformed T-cells have wild-type p53 genes [8 -
10]. Wild-type p53 is somehow stabilized post-translationally 
in HTLV-I-transformed T-cells [8]. Increased steady-state lev-
els of wild-type p53 protein are reported to be associated with 
its functional inactivation, and are thought to contribute to T-
cell transformation by HTLV-I [10,11]. 
In this study, we examined whether the aberrant expression 
and function of p53 protein is also observed in T-cells immor-
talized by T a x i . We found that p53 with the wild-type con-
formation was expressed at an elevated level by a post-tran-
scriptional mechanism, and that its /raws-activating function 
was impaired in Taxi-immortal ized T-cells as observed in 
many HTLV-I-transformed cells. 
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2. Materials and methods 
2.1. Cells and cell culture 
PBL/DGL-TaxlA and PBL/DGL-TaxlB are immortalized T-cell 
lines independently obtained from human peripheral blood lympho-
cytes (PBL) after infection with a Taxi-expressing retroviral vector 
[7]. Normal human CD4+ T-cells obtained from PBL using a CD4 
subset enrichment column (Cellect.plus HUMAN CD-4 KIT, Biotech) 
were initially stimulated with phytohemagglutinin (PHA) and re-
combinant IL-2. PBL/DGL-TaxlA, PBL/DGL-TaxlB, and normal 
human CD4+ T-cells were maintained in AIM-V medium (Gibco) 
containing 2% fetal bovine serum (FCS) and recombinant IL-2 at 
200 U/ml. MT-2 is an HTLV-I-infected T-cell line [12]. Jurkat is a 
human acute T-lymphoblastic leukemia cell line [13]. MT-2 and Jur-
kat were maintained in RPMI 1640 medium containing 10% FCS. 
J138V5C [14], a subline of Jurkat, is a stable transformant with a 
human temperature-sensitive p53 mutant p53Val~138, which behaves 
as wild type at low temperature (32°C) and as mutant type at high 
temperature (37°C). J138V5C cell line was maintained in RPMI 1640 
medium containing 10% FCS and G418 at 1.6 mg/ml. 
2.2. Immunoblotting 
Immunoblotting was performed essentially as previously described 
[7]. Briefly, 5x 105 cells were pelleted and lysed in 100 ul of 2XSDS-
PAGE sample buffer. After quantitating the protein with the BCA 
protein assay reagent (Pierce), each lysate corresponding to 5 ug of 
protein was fractionated on 10% SDS-PAGE, and then proteins were 
transferred to Immobilon filters (Millipore). After blocking with 5% 
nonfat dried milk in TBS (10 mM Tris-HCl, pH 7.4, 140 mM NaCl) 
overnight at room temperature, the membranes were incubated with 
mouse anti-p53 monoclonal antibody Ab-6 (Oncogene Science) in 
blocking buffer for 1 h. The membranes were then washed extensively 
with TBS containing 0.1% Tween 20, incubated for 1 h at room 
temperature with horseradish peroxidase-conjugated sheep anti-mouse 
IgG antibody, washed and developed with the ECL chemilumines-
cence reagent (Amersham) as directed by the manufacturer. 
2.3. Immunoprecipitation 
Cells (2X106) were pelleted and lysed in 200 |il of 1% NP40 lysis 
buffer containing 10 mM Tris-HCl (pH 8.0), 150 mM NaCl, 10% 
glycerol, 2.5 mM EDTA, 2 mM Na3V04 , 50 mM NaF, 20 mM 
Na4P207 , 1 mM PMSF, 10 mg/ml leupeptin, 1% aprotinin at 4°C 
for 20 min. Insoluble material was removed by centrifugation at 
4°C for 20 min at lOOOOXg. Cell lysates were incubated with anti-
p53 monoclonal antibodies PAM801, PAb240, and PAM620 (Ab-2, 3 
and 5, Oncogene Science) for 2 h at 4°C. PAM801 reacts with both 
wild-type and mutant p53 [15], PAb240 reacts preferentially with mu-
tant p53 [16], and PAM620 reacts preferentially with wild-type p53 
[17]. Immune complexes were precipitated by incubation with protein 
G-agarose for 1 h at 4°C. Immunoprecipitates were analyzed by SDS-
PAGE followed by immunoblotting with rabbit polyclonal anti-p53 
antibody RSP53(Nichirei). 
2.4. Northern blot analysis 
Total cellular RNA (10 ug) was resolved by electrophoresis in 1.0% 
agarose containing formaldehyde and MOPS, then blotted onto a 
nitrocellulose membrane. The membrane was hybridized with 32P-la-
beled probe, washed with 0.2XSSC and 0.1% SDS at 65°C for 1 h, 
then exposed to X-ray film with intensifying screens at —70°C. The 
probe for human p53 was obtained by RT-PCR based on the se-
quence data [18] and was confirmed by DNA sequencing. It contained 
almost the entire coding region of p53. 
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3. Results and discussion 
Fig. 1. Immunoblot analysis of p53 protein. Whole cell lysate corre-
sponding to 5 ug of protein was subjected to immunoblot analysis 
with mouse anti-p53 monoclonal antibody Ab-6 (Oncogene Science). 
The p53 band is indicated by an arrow. Lanes: 1, normal human 
CD4+ T-cells prepared from PBL as described in Section 2; 2, 
PBL/DGL-Taxl A; 3, PBL/DGL-Taxl B; 4, MT-2. PBL/DGL-
TaxlA and PBL/DGL-TaxlB are Taxi-immortalized T-cell lines in-
dependently established from PBL. 
2.5. Luciferase assay 
Luciferase reporter plasmids were introduced into T-cells by elec-
troporation as described previously [5]. One day after electroporation, 
cells were harvested and luciferase activities were measured with the 
PicaGene luciferase assay system (Toyo Ink) as directed by the man-
ufacturer. Reporter plasmids used were pCAST2Bluc, p-55Bluc, and 
pCMV-Luc. pCAST2Bluc has two copies of a consensus p53 binding 
sequence upstream of the interferon-P basal promoter, and p-55Bluc 
has only the interferon-P basal promoter [19]. pCMV-Luc was con-
structed by inserting a Xba\-Hind\\l fragment from pCMV-CAT [5] 
containing the human cytomegalovirus immediate early region pro-
moter into the Smal-Hindlll site of PGV-B2 (Toyo Ink) after end-
filling the Xbal site. 
3.1. Expression of p53 in Taxi-immortalized T-cell lines 
Steady-state expression levels of p53 protein in two individ-
ual Taxi-immortalized T-cell lines, PBL/DGL-Taxl A and 
PBL/DGL-TaxlB, were examined by immunoblot analysis. 
Both of these T-cell lines showed markedly increased p53 
protein expression compared to normal human CD4+ T cells 
(Fig. 1), and this level of expression was almost the same as 
that of the HTLV-I transformed T-cell line MT-2. To deter-
mine the conformational phenotype of the p53 protein ex-
pressed in these cells, we performed immunoprecipitation as-
says using three monoclonal antibodies, PAM801, PAb240, 
and PAM620 (Fig. 2). PAbl801 immunoprecipitates p53 pro-
tein in both wild-type and mutant conformation, PAb240 im-
munoprecipitates mutant forms of the protein, and PAM620 
immunoprecipitates wild-type forms of the protein [15-17]. In 
two Taxi-immortalized T-cell lines as well as in MT-2 cells, 
PAM801 and PAM620 precipitated equivalent amounts of 
p53, and only a very small amount of p53 was precipitated 
by PAb240. These results indicated that most of the p53 pro-
tein expressed in Taxi-immortalized T-cell lines as well as in 
MT-2 cells had the wild-type conformation. Northern blot 
analysis revealed that the levels of p53 mRNA did not differ 
significantly between normal CD4+ T-cells, PBL/DGL-
TaxlA, PBL/DGL-TaxlB, and MT-2 cells (Fig. 3). Thus, 
the level of wild-type p53 protein was increased post-tran-
scriptionally in Taxi-immortalized T-cell lines, probably due 
to prolongation of protein half-life as is the case with HTLV-
I-transformed T-cells. 
Fig. 2. Immunoprecipitaion of p53 protein. p53 was immunoprecipi-
tated with mouse monoclonal anti-p53 antibody PAbl801 (lanes 1, 
4, 7), PAb240 (lanes 2, 5, 8), and PAM620 (lanes 3, 6, 9). Immuno-
precipitates were then subjected to immunoblot analysis with rabbit 
polyclonal anti-p53 antibody RSP53 (Nichirei). PAM801 and 
RSP53 react with both wild-type and mutant p53, PAb240 reacts 
preferentially with mutant p53, and PAbl620 reacts preferentially 
with wild-type p53. We confirmed that PAb240 could immunopreci-
pitate mutant p53 in CEM cells under our experimental conditions 
(data not shown). Lanes: 1-3, PBL/DGL-Taxl B; 4-6, PBL/DGL-
Taxl A; 7-9, MT-2. 
Fig. 3. Northern blot analysis of p53 mRNA. Total cellular RNA 
(10 |ag) was subjected to Northern blot analysis with p53-specific 
probe. Ethidium bromide staining of rRNAs is shown in the lower 
panel. The sizes of the bands are indicated on the right. Lanes: 
1, MT-2; 2, normal human CD4+ T-cells; 3, PBL/DGL-Taxl A; 
4, PBL/DGL-Taxl B. 
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5 ug of pCAST2Bluc, p-55Bluc, and pCMV-Luc were transfected into 
each cell line by electroporation. J138V5C cells were prepared as two 
sets. Following 4 h incubation at 37°C, one set of the J138V5C cells 
was transferred to 32°C and the other was kept at 37°C. About 24 h 
after electroporation, cells were harvested and luciferase activities 
were measured. pCAST2Bluc has two copies of the consensus p53 
binding sequence upstream of the interferon-(3 basal promoter, and 
p-55Bluc has only the interferon-p" basal promoter. p53-mediated 
transactivation is presented as fold induction, which was determined 
by dividing the activity seen in cells transfected with pCAST2Bluc by 
that seen in cells transfected with p-55Bluc. Prior to it, each activity 
was normalized against the activity seen in cells transfected with 
pCMV-Luc to correct the differences in the transfection efficiency 
between each cell line. The results are the average ± standard devia-
tions of three independent experiments. 
3.2. Function of p53 in Taxi-immortalized T-cell lines 
The transactivating function of p53 in Taxi-immortalized 
T-cell lines was examined. A luciferase reporter plasmid con-
taining two copies of a consensus p53 binding sequence 
(pCAST2Bluc) and the reporter plasmid with no p53 binding 
sequence (p-55Bluc) were transfected into cells, and luciferase 
activities were measured. To evaluate the level of p53-medi-
ated transactivation, we used the J138V5C cell line as a con-
trol. J138V5C is a subline of Jurkat stably transformed with a 
human temperature-sensitive p53 mutant p53Val~138 [14]. At 
non-permissive temperature (37°C), p53Val~138 behaves as mu-
tant type and J138V5C cells grow normally. However, at per-
missive temperature (32°C), p53Val~138 behaves as wild type 
and J138V5C cells undergo apoptosis. It has been demon-
strated that the transactivating activity of p53Val~138 is equiv-
alent to that of wild-type p53 at permissive temperature but is 
almost undetectable at non-permissive temperature [20]. The 
value of p53-mediated transactivation, which was determined 
by dividing the activity seen in cells transfected with pCAST2-
Bluc with that seen in cells transfected with p-55Bluc, was 
more than 1000 in J138V5C cells at 32°C (Table 1). In con-
trast, the values of p53-mediated transactivation in the two 
Taxi-immortalized T-cell lines and in the MT-2 cell line were 
much lower and were only 7-14, which were equivalent to 
that in J138V5C cells at 37°C. Therefore, the level of p53-
mediated transactivation in J138V5C cells at 32°C was 70-
140 times higher than that in Taxi-immortalized T-cells and 
MT-2 cells. When protein expression levels were compared, 
J138V5C cells expressed 10-fold greater amounts of p53 pro-
tein than the Taxi-immortalized T-cell lines and the MT-2 cell 
line (Fig. 4). To determine whether the difference in expres-
sion levels could account for the differences in the levels of 
transactivation, the dose-response relation of p53-mediated 
transactivation was analyzed. pCAST2Bluc was co-transfected 
with increasing amounts of wild-type p53 expressing vector 
pCMVp53w [20] into Jurkat cells expressing no endogenous 
p53 protein, and the luciferase activity was measured. As 
shown in Fig. 5, it was clear that a 10-fold increase in the 
level of expression did not result in an increase in transacti-
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Fig. 4. Comparison of p53 protein levels. Whole cell lysate corre-
sponding to the indicated amount of protein was subjected to im-
munoblot analysis with mouse anti-p53 monoclonal antibody Ab-6 
(Oncogene Science). The band for p53 is indicated by an arrow. 
Lanes: 1, PBL/DGL-Taxl A cultured at 37°C; 2, PBL/DGL-Taxl 
B cultured at 37°C; 3, MT-2 cultured at 37°C; 4-8, J138V5C cul-
tured at 32°C for 24 h. 
vation equivalent to that observed in J138V5C cells at 32°C. 
Our data from this dose-response analysis were consistent 
with a previous report [21]. Thus, these results strongly sug-
gest that p53 in Taxi-immortalized T-cells as well as in MT-2 
cells was functionally impaired even though it had wild-type 
conformation. 
3.3. Conclusion 
In this study we found that the steady-state p53 protein 
level significantly increased in Taxi-immortalized T-cell lines 
4-| . 
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Fig. 5. Dose-response analysis of p53-mediated transactivation. In-
creasing amounts of pCMVp53w (wild-type p53 expression vector) 
were co-transfected with 5 ug of pCAST2Bluc (luciferase reporter 
plasmid containing p53 binding sites) into Jurkat cells, and lucifer-
ase activities were assayed. To equalize the total amount of DNA 
transfected in each experiment, appropriate amounts of pKS/CMV 
(empty backbone vector) were added. Values are averages of two in-
dependent experiments. Within this range of DNA amounts, we 
confirmed by using pCMV-Luc that the product increased linearly 
with an increase in the transfected expression vector plasmid (data 
not shown). RLU, relative light units. 
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compared to normal T-cells, al though the p53 protein ex-
pressed was conformationally wild-type. There were no signif-
icant changes in the p53 m R N A levels, suggesting that p53 
was elevated by a post-transcriptional mechanism. Luciferase 
assays with a reporter plasmid containing synthetic p53 bind-
ing sites revealed that the transactivating function of p53 was 
severely impaired in Taxi-immortal ized T-cells. All these re-
sults strongly suggest an important role for Tax i in the aber-
rant expression and function of p53 observed in many HTLV-
I transformed cells. However, it seems that Tax i does not 
directly induce such changes in p53, since the early passage 
of Taxi- t ransduced primary T-cells does not show any 
changes in the expression and function of p53, and this aber-
ration of p53 expression and function is observed only in fully 
immortalized cells such as P B L / D G L - T a x l A and PBL/DGL-
T a x l B described in this study (Akagi et al., unpublished 
data). Dysfunction of p53 may be a rather late event in the 
Taxi- induced immortalization process. Functional inactiva-
tion of p53 has been reported to be an important step in 
immortalization in many systems [22-28], and investigation 
of the mechanism by which the p53 function is impaired in 
Taxi-immortal ized T-cells may be necessary to understand the 
process of T-cell transformation by HTLV-I . 
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